GlassScriptPhysician profile
David E Kershner
NPI 1144304429
$1,920.78
in general payments reported to CMS, 2019-2025
21 companies · $203 in 2025
The $203 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $660 · 2022: $430 · 2023: $373 · 2024: $255 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $747 · Education: $84.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $746.60 |
| Education | $84.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $344.21 | 2021-2024 | Xyosted |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.98 | 2021-2025 | |
| Abbvie INC. | $213.37 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $182.43 | 2021-2025 | |
| Horizon Therapeutics Plc | $174.79 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $153.60 | 2023-2025 | |
| Novo Nordisk INC | $118.16 | 2021-2025 | Wegovy, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.57 | 2021-2023 | Xifaxan |
| Lilly USA, LLC | $70.54 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Avanir Pharmaceuticals, INC. | $67.55 | 2021-2022 | |
| Halozyme INC | $53.56 | 2023 | |
| Abbott Laboratories | $34.25 | 2022-2023 | Freestyle Libre 2 |
| Philips North America LLC | $28.37 | 2024 | (Ck7) Extended Holter |
| Merck Sharp & Dohme LLC | $25.85 | 2021 | |
| Alexion Pharmaceuticals, INC. | $23.36 | 2025 | Koselugo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $21.03 | 2023 | Veozah |
| Pfizer INC. | $18.22 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.88 | 2022 | |
| Radius Health, INC. | $17.73 | 2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $15.04 | 2021 | |
| Currax Pharmaceuticals LLC | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kershner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.